

Immediately after the title of the application, please insert the following:


-- CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of priority under 37 C.F.R. §1.78(a)(3) of United States Provisional Patent Application Number 60/265,304, filed January 31, 2001. --

After the last page of the claims, add the following abstract:

-- ABSTRACT OF THE INVENTION

This application is directed to compounds of the formula



wherein j is 1; k is 0 or 1; m is 1, 2 or 3; n is 1 or 2; W^1 and W^2 are independently -O- or -S(=O)-, where t is 0, 1, or 2; Y is $=C(R^1)_a-$, where R^1_a is a member selected from the group consisting of H; F; Cl; CN; NO_2 ; $-(C_1-C_4)$ alkyl; $-(C_2-C_4)$ alkynyl; fluorinated- (C_1-C_3) alkyl; fluorinated- (C_1-C_3) alkoxy; $-OR^{16}$; and $-C(=O)NR^{22}_aR^{22}_b$; R^{22}_a and R^{22}_b are defined as set forth in the specification; R^A and R^B are each a member independently selected from the group consisting of H; F; CF_3 ; $-(C_1-C_4)$ alkyl; $-(C_3-C_7)$ cycloalkyl; phenyl; and benzyl; wherein said cycloalkyl, phenyl, and benzyl moieties are each independently substituted with 0 to 3 substituents R^{10} , which is defined as set forth in the specification; R^{16} and R^{17} are defined as set forth in the specification; $-R^C$ and R^D have the same meaning as defined above for R^A and R^B except that one of them must be -H, and they are selected independently of each other and of R^A and R^B ; R^1 and R^2 are each a member independently selected from the group consisting of H; F; Cl; CN; NO_2 ; $-(C_1-C_4)$ alkyl; $-(C_2-C_4)$ alkynyl; fluorinated- (C_1-C_3) alkyl; OR^{16} ; and $-C(=O)NR^{22}_aR^{22}_b$; R^3 is H; $-(C_1-C_3)$ alkyl; phenyl; benzyl; or OR^{16} ; R^4 , R^5 and R^6 are defined as set forth in the specification; J^1 and J^2 are each independently a moiety comprising a saturated or unsaturated six-membered monocyclic carbon ring; and D is a member independently selected from the group consisting of partial Formulas (1.1.1) through (1.1.5) as set forth in the specification; a pharmaceutically acceptable salt thereof; which are useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructive pulmonary disease. --

Applicants have enclosed a copy of the abstract on a separate page herewith, consecutively numbered with the last page of the claims.